Development and Evaluation of a Modified Fixed-Dose Combination Antihypertensive Tablet Containing S-Amlodipine Besylate: A Bioequivalence and Stability Study
This study evaluates a new fixed-dose combination tablet containing S-amlodipine, highlighting its bioequivalence and stability compared to traditional combinations.
Key Points
The newly developed S-amlodipine besylate tablet offers improved safety and efficacy for hypertension treatment, and may enhance patient adherence.
In vivo pharmacokinetic studies confirmed the bioequivalence of the modified formulation to existing treatments for hypertension.
Dissolution testing showed the stability and pharmaceutical equivalence of the new formulation against reference fixed-dose combinations.
The use of S-amlodipine is expected to reduce adverse effects commonly associated with racemic amlodipine, benefiting patients.